

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

14 Jun 2026

### **effect of Hesperidin,Artemisinin- Artemisia annua, Noscaphine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19**

#### **Protocol summary**

##### **Study aim**

Determination of the effect of Hesperidin,Artemisinin- Artemisia annua, Noscaphine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

##### **Design**

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 per 100 patients. Block randomization method was used .

##### **Settings and conduct**

The study will be performed at Imam Reza Hospital in Sirjan. 25 patients in all four groups with symptomatic Covid-19 virus will be identified with the same .Hesperidin,Artemisinin- Artemisia annua, Noscaphine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C With specific doses will be received in the intervention groups and the control groups will receive the National Protocol of the Ministry of Health. In this study, the work will be a double-blind clinical trial (Participant, Evaluator, Data analyst, Data safety and Monitoring committee)

##### **Participants/Inclusion and exclusion criteria**

Inclusion criteria: COVID-19 virus infection,Clinical symptoms, Lymphocytes less than 15%, Lung involvement in CT scan, Oxygen level less than 93%, Unstable vital signs Exclusion criteria: Allergy to oral supplements and high doses of vitamin C, Pregnant and lactating women, Patients with seizures Dialysis patients

##### **Intervention groups**

Intervention group: non-hospitalization patients received Supplements and high dose of vitamin C Intervention group: hospitalization patients received Supplements and high dose of vitamin C Control group: non-hospitalization patients received Protocol of the Ministry of Health Control group: hospitalization patients received

Protocol of the Ministry of Health

##### **Main outcome variables**

LDH, CBC diff, Na / K / Ca, CRP, ESR1, Weakness and nausea, Respiratory quality

#### **General information**

##### **Reason for update**

##### **Acronym**

##### **IRCT registration information**

IRCT registration number: **IRCT20181030041504N1**

Registration date: **2020-11-08, 1399/08/18**

Registration timing: **retrospective**

Last update: **2020-11-08, 1399/08/18**

Update count: **0**

##### **Registration date**

2020-11-08, 1399/08/18

##### **Registrant information**

##### **Name**

masoomeh mohamadpour

##### **Name of organization / entity**

##### **Country**

Iran (Islamic Republic of)

##### **Phone**

+98 21 8860 7357

##### **Email address**

mohamadpour.m@iums.ac.ir

##### **Recruitment status**

**Recruitment complete**

##### **Funding source**

##### **Expected recruitment start date**

2020-10-07, 1399/07/16

##### **Expected recruitment end date**

2020-11-05, 1399/08/15

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

**Public title**

Evaluation of the combined effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

COVID-19 virus infection by RT-PCR in non-hospitalization and hospitalization patients G6PD sufficient in non-hospitalization and hospitalization patients Lack of clinical response to routine outpatient treatment in non-hospitalization and hospitalization patients Clinical symptoms (fever, cough, myalgia, shortness of breath, digestive problems) in non-hospitalization and hospitalization patients Age over 12 years in non-hospitalization and hospitalization patients Patient satisfaction in non-hospitalization and hospitalization patients Lymphocytes less than 15%, respiratory distress, lung involvement on CT scan, oxygen level less than 93%, unstable vital signs, severe gastrointestinal symptoms and oral intolerance, underlying disease Except for exclusion cases hospitalization patients

**Exclusion criteria:**

Allergy to oral supplements and high doses of vitamin C Reluctance to continue participating in the trial for any reason Patients admitted to the intensive care unit (ICU) (patients who have been admitted to the ICU since admission) Pregnant and lactating lady Patients with seizures Dialysis patients

**Age**

From **12 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: **100**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

For this purpose, we will use the quadruple block method (Block Randomization). Random allocation software will be used for this purpose. We prepare two sheets of paper. On a sheet we write the letter I meaning "Intervention" and on a sheet the letter S means "Standard treatment". Mix the sheets together and place them in the desk drawer. With the referral of each eligible patient, one of the leaflets will be randomly taken out and based on this extracted leaflet will be assigned to one of the two intervention groups. It should be noted that the pulled out sheets will not be returned to the drawer until all four sheets have been pulled out. After accidentally pulling out all four sheets, all the sheets are returned to the drawer and the above procedure will be continued for the next four patients until the desired sample size is reached.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Participant, Evaluator, Data analyst, Data safety and Monitoring committee

**Placebo**

Not used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

sirjan faculty of medical science

**Street address**

sirjan - Seyyed Jamaledin Asad Abadi Blvd - Parks of Traffic - Sirjan University of Medical Sciences

**City**

sirjan

**Province**

Kerman

**Postal code**

7816916338

**Approval date**

2020-10-07, 1399/07/16

**Ethics committee reference number**

IR.SIRUMS.REC.1399.033

**Health conditions studied**

**1**

**Description of health condition studied**

covid-19

**ICD-10 code**

RA01.0

**ICD-10 code description**

Severe Acute Respiratory Syndrome coronavirus

**Primary outcomes**

**1**

**Description**

LDH

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

Blood Test

**2**

**Description**

CBC diff

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

Blood Test

**3**

**Description**

Na/K/Ca

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

Blood Test

**4**

**Description**

CRP

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

Blood Test

**5**

**Description**

ESR1

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

Blood Test

**6**

**Description**

Weakness and nausea

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

Check List

**7**

**Description**

Lung involvement

**Timepoint**

Before the intervention and ten days after the intervention

**Method of measurement**

CT-Scan

**Secondary outcomes**

**1**

**Description**

Determination of the effect of Hesperidin,Artemisinin-Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on oxygen

**Timepoint**

10 day

**Method of measurement**

Pulse Oximeter

**2**

**Description**

General condition of people and vitality after treatment

**Timepoint**

10 day

**Method of measurement**

Examination and history

**Intervention groups**

**1**

**Description**

Intervention group: non-hospitalization patients with symptomatic COVID-19 received 1. Artemisia annua - Artemisinin ( Manufactured by Longlifenutri)150 mg every 24 hours 2. Dose of 1 g of vitamin C (Manufactured by Daroupakhsh) intravenous vitamin (2 ampoules of 500 mg in 250 cc of sodium chloride serum for 30 minutes) every 24 hours 3. Dose of 5 cc of noscapine ( Manufactured by Faran Shimi) each Eight hours 4. 500 mg dose of hesperidin (Manufactured by Swanson) every 24 hours 5. Resveratrol 500 mg (Manufactured by A Squard) every 24 hours 6. NAC 600 mg ( Manufactured by Osvah ) every 12 hours . The duration of treatment is estimated at ten days. Supplements are taken orally and vitamin C is given to patients as an injection

**Category**

Treatment - Drugs

**2**

**Description**

Control group: non-hospitalization patients with

symptomatic COVID-19 Protocol of the Ministry of Health

### Category

Treatment - Drugs

## 3

### Description

Intervention group: hospitalization patients with symptomatic COVID-19 received 1. Artemisia annua - Artemisinin ( Manufactured by Longlifenutri)150 mg every 12hours 2. Dose of 1 g of vitamin C (Manufactured by Daroupakhsh) intravenous vitamin (2 ampoules of 500 mg in 250 cc of sodium chloride serum for 30 minutes) every 12 hours 3. Dose of 5 cc of nospapine ( Manufactured by Faran Shimi) each Eight hours 4. 500 mg dose of hesperidin (Manufactured by Swanson) every 24 hours 5. Resveratrol 500 mg (Manufactured by A Squad) every 24 hours 6. NAC 600 mg ( Manufactured by Osvah ) every 12 hours . The duration of treatment is estimated at ten days. Supplements are taken orally and vitamin C is given to patients as an injection

### Category

Treatment - Drugs

## 4

### Description

Control group: hospitalization patients with symptomatic COVID-19 Protocol of the Ministry of Health

### Category

Treatment - Drugs

## Recruitment centers

## 1

### Recruitment center

#### Name of recruitment center

بیمارستان امام رضا

#### Full name of responsible person

دکتر علی امجدی

#### Street address

خیابان هجرت - بیمارستان امام رضا

#### City

سیرجان

#### Province

Kerman

#### Postal code

7816916338

#### Phone

+98 34 4152 4452

#### Email

Aamjadi50@yahoo.com

#### Web page address

<http://emamrezahp.sirums.ac.ir/>

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Sirjan Faculty of Medical Science

### Full name of responsible person

Dr.Mahood reza Masoudi

### Street address

Seyyed Jamaledin Asad Abadi Blvd - Parks of Traffic

### City

Sirjan

### Province

Kerman

### Postal code

7816916338

### Phone

+98 34 4227 3696

### Email

ssm@sirums.ac.ir

### Web page address

[http://www.sirums.ac.ir/index.php?option=com\\_content&view=featured&Itemid=102&lang=en](http://www.sirums.ac.ir/index.php?option=com_content&view=featured&Itemid=102&lang=en)

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Sirjan Faculty of Medical Science

### Proportion provided by this source

100

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Sirjan Faculty of Medical Science

#### Full name of responsible person

Dr.Ali,Amjadi

#### Position

Non-faculty specialist physician

#### Latest degree

Specialist

#### Other areas of specialty/work

Infectious diseases

#### Street address

Seyyed Jamaledin Asad Abadi Blvd - Parks of Traffic

#### City

Sirjan

#### Province

Kerman

#### Postal code

7816916338

#### Phone

+98 34 4234 0640

#### Email

Aamjadi50@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Rayan Research Company

**Full name of responsible person**

Dr. Masoomeh Mohamadpour

**Position**

Managing Director

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Anatomical-cellular and molecular sciences

**Street address**

No 16, Gisha Ave

**City**

tehran

**Province**

Tehran

**Postal code**

1448643643

**Phone**

+98 21 8827 5219

**Email**

m.mohamadpour2817@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Rayan Research Company

**Full name of responsible person**

Dr. Masoomeh Mohamadpour

**Position**

Managing Director

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Anatomical-cellular and molecular sciences

**Street address**

No. 16, Gisha Ave

**City**

tehran

**Province**

Tehran

**Postal code**

1448643643

**Phone**

+98 21 8827 5219

**Email**

m.mohamadpour2817@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available

**Title and more details about the data/document**

Main outcome data, statistical analysis, final report, informed consent form

**When the data will become available and for how long**

6 months after publish the results

**To whom data/document is available**

Academic researchers

**Under which criteria data/document could be used**

Master of Medical Sciences PhD in Medical Sciences specialist Contribute to the advancement of science

**From where data/document is obtainable**

Email m.mohamadpour2817@yahoo.com Contact number: 09120031782 Dr. Masoomeh Mohamadpour - Tehran

**What processes are involved for a request to access data/document**

48-72 hours after sending the email request

**Comments**